Production (Stage)
Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.16% | 37.40% | -93.75% | 29.26% | -21.29% |
| Total Depreciation and Amortization | -49.71% | -12.63% | -12.39% | -1.09% | -6.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -20.47% | -80.12% | 682.80% | -57.02% | 618.95% |
| Change in Net Operating Assets | -114.95% | 136.10% | -442.92% | 2,584.78% | -102.03% |
| Cash from Operations | -24.75% | 29.85% | -63.21% | 32.03% | -8.06% |
| Capital Expenditure | -88.64% | 24.14% | -107.14% | -7.69% | 67.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -88.64% | 24.14% | -107.14% | -7.69% | 67.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -200.00% | 50.00% | 33.33% | 0.00% |
| Issuance of Common Stock | -- | -- | -100.00% | -3.22% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.07% | 392,805.88% | -105.95% | 0.88% | 654.90% |
| Foreign Exchange rate Adjustments | -106.55% | 540.69% | -337.66% | -69.97% | -43.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -148.37% | 275.98% | -79.33% | 29.47% | -14.41% |